A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 (FRIENDS-01)
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Sponsor: The First Affiliated Hospital with Nanjing Medical University
This observational or N/A phase trial investigates CTIT: Cancer Therapy Induced Thrombocytopenia and is currently actively recruiting participants. The First Affiliated Hospital with Nanjing Medical University leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
2 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Status: Not Yet Recruiting → Recruiting · Phase: PHASE3 → None
-
Feb 2025 — Apr 2026 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Contact Information
- The First Affiliated Hospital with Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .